Glenmark Pharmaceuticals Limited (BSE: 532296 / NSE: GLENMARK)
Technical Analysis & Key Levels
-
Reference Closing Price: ₹ 2371
-
Immediate Support Level : ₹ 2323 – ₹2303
-
Strong Support Level : ₹ 2280 (Major swing base & structural demand zone)
-
Short-term Levels : ₹ 2390 – ₹2404
-
Bullish Breakout Point : Above ₹ 2404 – ₹ 2420
Company Overview
-
Business Profile: Leading research-driven global pharmaceutical company focused on branded generics, specialty formulations, and APIs across dermatology, respiratory, and oncology domains.
-
Face Value: ₹1
-
Promoter Holding: ~46.65% (backed by strong domestic and foreign institutional participation)
-
Financials & Outlook :
-
Quarterly Performance : Robust operational revenue trajectory (quarterly income scaling ₹2,200–₹2,400+ crore) with expanding EBITDA margins and strengthening net profitability.Growth Drivers : Global expansion of specialty respiratory products (like Ryaltris), product launches in dermatology, active debt deleveraging, and strong growth in domestic market share.Long-term View : Highly positive structural outlook driven by an expanding specialty pipeline, operational leverage, and disciplined balance sheet execution.
Disclaimer: Stock levels and commentary are shared strictly for illustration and are not buy, sell, or hold recommendations. Investments in the securities market are subject to market risks, carefully read and agree to all disclaimers and related documents on www.nikhilbhatt.in before investing.
